Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins.
Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins. The underlying immunological dysfunction involves autoreactive T cells, B cells producing pathogenic antibodies (anti-topoisomerase, anti-centromere), and dysregulated cytokine signalling (TGF-β, IL-6). Placental MSCs are being explored as an anti-inflammatory and immunomodulatory intervention, delivering cytokines and cell-surface molecules that suppress autoreactive immune cells and potentially reprogram fibroblast behaviour. Unlike conventional disease-modifying antirheumatic drugs (DMARDs), cell therapy aims to reset immune tolerance rather than merely suppress inflammation. Note: autologous haematopoietic stem-cell transplantation (HSCT) is an established, though intensive, option for severe early-stage systemic sclerosis in selected candidates, with demonstrated benefit in some clinical series.
| Costo indicativo · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Intervallo dei costi di mercato globale | €20,000–€27,500 (dvcstem.com) |
| Principali tipi di cellule studiati | MSC dalla membrana amniotica |
| Stato di approvazione | Investigazionale |
| Studi registrati (ClinicalTrials.gov) | 42 · 7 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Forty-two completed trials and 7 currently recruiting trials are registered for systemic sclerosis, with diverse cell sources (placental MSC predominating, alongside autologous bone-marrow-derived MSC and HSCT). HSCT trials have shown arrest or reversal of skin fibrosis in approximately 70–80% of treated patients, with sustained benefit at 5-year follow-up in many, though the treatment carries significant morbidity (infection risk, infertility, relapse). MSC trials are smaller and earlier-stage; published data show stabilisation of skin thickening (modified Rodnan skin score stability or improvement) in 50–70% of placental MSC-treated participants over 6–24 months, often accompanied by improved lung function and hand mobility.
Depending on assessment, a Scleroderma (Systemic Sclerosis) protocol may draw on:
Placental MSC infusion for scleroderma costs €5,000–8,500 per treatment course, with many protocols involving two to three infusions spaced weeks to months apart. Autologous HSCT is substantially more expensive (€35,000–60,000), reflecting hospitalisation, high-dose chemotherapy conditioning, stem-cell mobilisation and reinfusion, and intensive post-transplant monitoring. Baseline assessments (skin biopsy, pulmonary function, cardiac imaging) add €2,000–3,500. Long-term immunosuppression post-HSCT incurs ongoing medication costs.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Scleroderma (Systemic Sclerosis) cost-by-country breakdown, or compare the best countries for Scleroderma (Systemic Sclerosis) →
Before booking, check safety & regulation, the recovery climate, se potresti essere un candidato, and which cell type fits Scleroderma (Systemic Sclerosis).
FAQ completo Sclerodermia (Sclerosi Sistemica) → · Analisi dei costi Sclerodermia (Sclerosi Sistemica) →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sono un candidato? · Quale tipo di cellula? · Types of clinics & best countries · Calcolatore di costi
Rivisto medicalmente dal team editoriale di StemCellAtlas con Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita